4 Takeaways from BioXcel Therapeutics (BTAI) Management Meetings, Canaccord Genuity Reiterates Buy
Tweet Send to a Friend
Canaccord Genuity analyst Sumant Kulkarni reiterated a Buy rating and $84.00 price target on BioXcel Therapeutics (NASDAQ: BTAI) after hosting ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
